Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD2373 in Healthy Men of Sub-Saharan West African Ancestry
NCT05351047Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2022
- Primary completion
- Jul 2023
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of opemalirsen in APOL1-mediated kidney disease (AMKD) (5 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of subjects with adverse events and abnormal findings up to 21 weeks. Started Apr 2022; status: completed.
02
Drugs
opemalirsen
03
Conditions
APOL1-mediated kidney disease (AMKD)
Beyond the preview
Go deeper on NCT05351047.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05351047.